🧬 This addition complements their adeno-associated viral vector services.
🔬 Lentiviral vectors are gaining traction for gene therapies, treating genetic diseases and cancer.
💡 Their services offer customized, license-free solutions to expedite viral vector programs, enhancing support for therapeutic developers.
Introduction:
The article discusses the recent launch of a lentiviral vector manufacturing toolbox by Rentschler Biopharma at its facility in Stevenage, UK. This expansion aims to enhance their existing services for advanced therapy medicinal products (ATMPs), particularly focusing on gene therapies utilizing lentiviral vectors (LVVs).
- Rentschler Biopharma has introduced a lentiviral vector manufacturing toolbox to support development in the advanced therapy sector.
- The growing prominence of LVVs is attributed to positive clinical outcomes in treating various genetic diseases and in modifying T-cells for cancer immunity.
- CEO Christiane Bardroff emphasized Rentschler’s strategic investment in the cell and gene therapy market, initially focusing on adeno-associated viral (AAV) vector services.
- The advanced therapies facility offers license-free, customized solutions aimed at expediting viral vector programs at all development stages.
- The proprietary HEK293 cell line provided by Rentschler allows clients to achieve cost and time efficiencies in their therapy development projects.
Conclusion:
The introduction of the lentiviral vector manufacturing toolbox reflects Rentschler Biopharma’s commitment to addressing the increasing demands of the gene therapy industry. By expanding its capabilities, the company positions itself as a key player in the evolving field of advanced therapies, providing essential resources for therapeutic developers engaged in innovative treatments.
